Skip to main content

Liver Diseases

The Liver Diseases group is a referent at the local, national and international level in research, and is one of the most active groups in clinical research at VHIR. The group's prominent involvement in clinical trials is a clear indication of our professionals' commitment to ensuring that patients have access to state-of-the-art therapies. Our participation and collaboration in international projects and consortiums are also a fundamental characteristic of the group. The main objective of the group is to become one of the best translational research groups in liver diseases. It is essential to be able to apply all the findings of basic research to clinical research to improve the health of patients with liver disease.

Team

Laura Puente Ramo

Laura Puente Ramo

Liver Diseases
Read more
Lluis Castells Fusté

Lluis Castells Fusté

Liver Diseases
Read more
Lluís Viladomiu Catà

Lluís Viladomiu Catà

Liver Diseases
Read more
Lourdes Ruiz  Ortega

Lourdes Ruiz Ortega

Predoctoral researcher
Liver Diseases
Read more
Macarena Simon-Talero Horga

Macarena Simon-Talero Horga

Main researcher
Liver Diseases
Read more
María Bermúdez Ramos

María Bermúdez Ramos

Senior researcher
Liver Diseases
Read more
Laura Puente Ramo

Laura Puente Ramo

Liver Diseases
Read more
Lluis Castells Fusté

Lluis Castells Fusté

Liver Diseases
Read more
Lluís Viladomiu Catà

Lluís Viladomiu Catà

Liver Diseases
Read more
Lourdes Ruiz  Ortega

Lourdes Ruiz Ortega

Predoctoral researcher
Liver Diseases
Read more
Macarena Simon-Talero Horga

Macarena Simon-Talero Horga

Main researcher
Liver Diseases
Read more
María Bermúdez Ramos

María Bermúdez Ramos

Senior researcher
Liver Diseases
Read more

Projects

Impact of HLA haplotypes and HDV viremia in developing of clinical events and quality of life of patients with chronic hepatitis delta.

IP: Maria Buti Ferret
Collaborators: Maria Jose Herrero Mata, Ana Barreira Diaz, Maria del Mar Riveiro Barciela, Jordi Llaneras Artigues, Adriana Palom Agusti
Funding agency: Instituto de Salud Carlos III
Funding: 117370
Reference: PI20/01692
Duration: 01/01/2021 - 30/06/2025

Plataforma ISCIII de soporte para la Investigación Clínica

IP: Inmaculada Fuentes Camps
Collaborators: Gemma Vona Giralt, Antonio Moreno Galdó, Rafael Simó Canonge, Núria Pérez Picazo, Tamara Del Rio Higueras, Ariadna Martín Balcells, Olga Sánchez- Maroto Carrizo, Angelica Valderrama Rodríguez, Joan Genescà Ferrer, Paula Isabel Roldan Caballero
Funding agency: Instituto de Salud Carlos III
Funding: 315150
Reference: PT20/00078
Duration: 01/01/2021 - 31/12/2024

OPTIMIZACIÓN DE NUEVOS TRATAMIENTOS EN LA ENFERMEDAD HEPÁTICA CRÓNICA-NASH

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Maria Nieves Martell Pérez-Alcalde, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 268620
Reference: PI21/00691
Duration: 01/01/2022 - 30/06/2026

Determinación de biomarcadores de lesión neuronal y astrocitaria en suero de paciente con encefalopatía hepática

IP: Macarena Simon-Talero Horga
Collaborators: Joaquin Castillo Justribo, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 60500
Reference: PI21/00312
Duration: 01/01/2022 - 31/12/2024

Publications

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.

PMID: 37861218
Journal: NEW ENGLAND JOURNAL OF MEDICINE
Year: 2023
Reference: N Engl J Med. 2023 Oct 20. doi: 10.1056/NEJMoa2307980.
Impact factor:
Publication type: Paper in international publication
Authors: Abraldes, Juan Gonzalez; Ahn, Myung-Ju; Akamatsu, Hiroaki; Albillos, Agustin; Amitrano, Lucio; Anderson, Erik S; Balcar, Lorenz; Blackhall, Fiona; Borghaei, Hossein; Bosch, Jaime et al.
DOI: 10.1056/NEJMoa2307980

Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant.

PMID: 37870985
Journal: Hepatology Communications
Year: 2023
Reference: Hepatol Commun. 2023 Oct 18;7(11):e0273. doi: 10.1097/HC9.0000000000000273. eCollection 2023 Nov 1.
Impact factor:
Publication type: Paper in international publication
Authors: Albillos, Agustin; Ampuero, Javier; Andrade, Raul J; Angeli, Paolo; Arroyo, Vicente; Ballester, Maria Pilar; Belli, Luca; Berenguer, Marina; Berg, Thomas; Bongiovanni, Deborah et al.
DOI: 10.1097/HC9.0000000000000273

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.

PMID: 37871604
Journal: LANCET
Year: 2023
Reference: Lancet. 2023 Oct 19:S0140-6736(23)02033-0. doi: 10.1016/S0140-6736(23)02033-0.
Impact factor:
Publication type: Paper in international publication
Authors: Albillos, Agustin; Ampuero, Javier; Andrade, Raul J; Angeli, Paolo; Arroyo, Vicente; Bai, Yuxian; Ballester, Maria Pilar; Belli, Luca; Berenguer, Marina; Berg, Thomas et al.
DOI: 10.1016/S0140-6736(23)02033-0

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study.

PMID: 37879444
Journal: ANNALS OF ONCOLOGY
Year: 2023
Reference: Ann Oncol. 2023 Oct 17:S0923-7534(23)04281-3. doi: 10.1016/j.annonc.2023.10.117.
Impact factor:
Publication type: Paper in international publication
Authors: Augustin, Salvador; Azuma, K; Baneras, Jordi; Barala, P; Bauml, J M; Bearz, A; Boixadera, Anna; Bourla, A B; Califano, R; Campelo, R G et al.
DOI: 10.1016/j.annonc.2023.10.117

AEEH Consensus about detection and referral of hidden prevalent liver diseases.

PMID: 35569541
Journal: Gastroenterologia y Hepatologia
Year: 2022
Reference: Gastroenterol Hepatol. 2022 May 13. pii: S0210-5705(22)00137-6. doi: 10.1016/j.gastrohep.2022.04.001.
Impact factor: 2.102
Publication type: Paper in national publication
Authors: Romero-Gomez, Manuel, Aller, Rocio, Ampuero, Javier, Rodriguez, Conrado Fernandez, Augustin, Salvador, Latorre, Raquel, Rivera-Esteban, Jesus, Urroz, Belen Martinez, Garcia, Maria Luisa Gutierrez, Lopez, Sonia Alonso et al.
DOI: 10.1016/j.gastrohep.2022.04.001

Non-Invasive Tests of Liver Fibrosis Help in Predicting the Development of Hepatocellular Carcinoma among Patients with NAFLD.

PMID: 35566592
Journal: Journal of Clinical Medicine
Year: 2022
Reference: J Clin Med. 2022 Apr 27;11(9). pii: jcm11092466. doi: 10.3390/jcm11092466.
Impact factor: 4.242
Publication type: Paper in international publication
Authors: Banares, Juan, Bermudez, Maria, Vargas, Victor, Salcedo-Allende, Maria Teresa, Castells, Lluis, Augustin, Salvador, Minguez, Beatriz, Pericas, Juan M, Manzano, Ramiro, Rivera-Esteban, Jesus et al.
DOI: 10.3390/jcm11092466

Value of pilot studies in alcohol-associated hepatitis.

PMID: 35567756
Journal: LIVER INTERNATIONAL
Year: 2022
Reference: Liver Int. 2022 Jul;42(7):1697. doi: 10.1111/liv.15291. Epub 2022 May 23.
Impact factor: 5.828
Publication type: Letter or abstract
Authors: Ventura-Cots, Meritxell, Bataller, Ramon, Vargas, Victor, Jimenez, Cesar et al.
DOI: 10.1111/liv.15291

Cost-effectiveness analysis of an active search to retrieve HCV patients lost to follow-up (RELINK-C strategy) and the impact of COVID-19.

PMID: 35555847
Journal: JOURNAL OF VIRAL HEPATITIS
Year: 2022
Reference: J Viral Hepat. 2022 Jul;29(7):579-583. doi: 10.1111/jvh.13686. Epub 2022 May 23.
Impact factor: 3.728
Publication type: Paper in international publication
Authors: Vargas-Accarino, Elena, Martinez-Camprecios, Joan, Dominguez-Hernandez, Raquel, Rando-Segura, Ariadna, Riveiro-Barciela, Mar, Rodriguez-Frias, Francisco, Barreira, Ana, Palom, Adriana, Casado, Miguel Angel, Esteban, Rafael et al.
DOI: 10.1111/jvh.13686

Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.

PMID: 33720484
Journal: JOURNAL OF VIRAL HEPATITIS
Year: 2021
Reference: J Viral Hepat. 2021 Sep;28(9):1319-1324. doi: 10.1111/jvh.13497. Epub 2021 Mar 22.
Impact factor: 3.728
Publication type: Paper in international publication
Authors: Buti, Maria, Esteban, Juan Ignacio, Quer, Josep, Campos, Carolina, Tabernero, David, Canizares, Angelina, Castro-Iglesias, Angeles, Garcia-Cehic, Damir, Rando, Ariadna, Rodriguez-Frias, Francisco et al.
DOI: 10.1111/jvh.13497

Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B.

PMID: 33614029
Journal: Therapeutic advances in infectious disease
Year: 2021
Reference: Ther Adv Infect Dis. 2021 Feb 5;8:2049936120985954. doi: 10.1177/2049936120985954. eCollection 2021 Jan-Dec.
Impact factor: 0
Publication type: Review in international publication
Authors: Roade, Luisa, Riveiro-Barciela, Mar, Esteban, Rafael, Buti, Maria et al.
DOI: 10.1177/2049936120985954

Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patients.

PMID: 33603102
Journal: Scientific Reports
Year: 2021
Reference: Sci Rep. 2021 Feb 18;11(1):4215. doi: 10.1038/s41598-021-83762-4.
Impact factor: 4.38
Publication type: Paper in international publication
Authors: Pacin Ruiz, Beatriz, Garcia-Garcia, Selene, Esteban-Mur, Rafael, Tabernero, David, Buti, Maria, Rodriguez-Frias, Francisco, Lopez-Martinez, Rosa, Rando, Ariadna, Quer, Josep, Yll, Marcal et al.
DOI: 10.1038/s41598-021-83762-4

Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884].

PMID: 33317846
Journal: JOURNAL OF HEPATOLOGY
Year: 2021
Reference: J Hepatol. 2021 Feb;74(2):491. doi: 10.1016/j.jhep.2020.11.020. Epub 2020 Dec 11.
Impact factor: 25.083
Publication type: Letter or abstract
Authors: Marino, Zoe, Darnell, Anna, Lens, Sabela, Sapena, Victor, Diaz, Alba, Belmonte, Ernest, Perello, Christie, Calleja, Jose Luis, Varela, Maria, Rodriguez, Manuel et al.
DOI: 10.1016/j.jhep.2020.11.020

Editorial: rapid disease progression in hepatitis delta-can we turn the tide? Authors' reply.

PMID: 31850577
Journal: ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Year: 2020
Reference: Aliment Pharmacol Ther. 2020 Jan;51(1):174-175. doi: 10.1111/apt.15558.
Impact factor: 7.515
Publication type: Editorail in international publication
Authors: Palom, Adriana, Riveiro-Barciela, Mar, Buti, Maria et al.
DOI: 10.1111/apt.15558

Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.

PMID: 31607677
Journal: Lancet Gastroenterology & Hepatology
Year: 2020
Reference: Lancet Gastroenterol Hepatol. 2020 Jan;5(1):31-41. doi: 10.1016/S2468-1253(19)30320-6. Epub 2019 Oct 10.
Impact factor: 14.789
Publication type: Paper in international publication
Authors: Jimenez, Cesar, Pose, Elisa, Napoleone, Laura, Amin, Ahmed, Campion, Daniela, Sola, Elsa, Uschner, Frank Erhard, de Wit, Koos, Zaccherini, Giacomo, Alessandria, Carlo et al.
DOI: 10.1016/S2468-1253(19)30320-6

Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia.

PMID: 31721254
Journal: ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Year: 2020
Reference: Aliment Pharmacol Ther. 2020 Jan;51(1):158-166. doi: 10.1111/apt.15521. Epub 2019 Nov 13.
Impact factor: 7.515
Publication type: Paper in international publication
Authors: Esteban, Rafael, Buti, Maria, Rodriguez, Manuel, Lens, Sabela, Riveiro-Barciela, Mar, Garcia-Samaniego, Javier, Palom, Adriana, Rodriguez-Tajes, Sergio, Navascues, Carmen A et al.
DOI: 10.1111/apt.15521

Hepatitis C virus genotype 4: Genotype 1's little brother.

PMID: 27905173
Journal: JOURNAL OF VIRAL HEPATITIS
Year: 2017
Reference: J Viral Hepat. 2017 Jan;24(1):4-12. doi: 10.1111/jvh.12620. Epub 2016 Dec 1.
Impact factor: 4.122
Publication type: Review in international publication
Authors: Esteban, R, Buti, M, Llaneras, J, Riveiro-Barciela, M et al.
DOI: 10.1111/jvh.12620

High Hcv subtype heterogeneity in a chronically infected general population Revealed by high-Resolution Hcv subtyping.

PMID: 28192235
Journal: CLINICAL MICROBIOLOGY AND INFECTION
Year: 2017
Reference: Clin Microbiol Infect. 2017 Oct;23(10):775.e1-775.e6. doi: 10.1016/j.cmi.2017.02.007. Epub 2017 Feb 10.
Impact factor: 5.292
Publication type: Paper in international publication
Authors: Ordeig, Laura, Rodriguez-Frias, Francisco, Nieto, Leonardo, Gregori, Josep, Garcia-Cehic, Damir, Casillas, Rosario, Tabernero, David, Homs, Maria, Blasi, Maria, Vila, Marta et al.
DOI: 10.1016/j.cmi.2017.02.007

Genetic diagnosis of alpha1-antitrypsin deficiency using DNA from buccal swab and serum samples.

PMID: 28107169
Journal: CLINICAL CHEMISTRY AND LABORATORY MEDICINE
Year: 2017
Reference: Clin Chem Lab Med. 2017 Aug 28;55(9):1276-1283. doi: 10.1515/cclm-2016-0842.
Impact factor: 3.432
Publication type: Paper in international publication
Authors: Belmonte, Irene, Barrecheguren, Miriam, Esquinas, Cristina, Rodriguez, Esther, Miravitlles, Marc, Rodriguez-Frias, Francisco et al.
DOI: 10.1515/cclm-2016-0842

Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.

PMID: 28078526
Journal: DIGESTIVE DISEASES AND SCIENCES
Year: 2017
Reference: Dig Dis Sci. 2017 Mar;62(3):784-793. doi: 10.1007/s10620-017-4448-7. Epub 2017 Jan 11.
Impact factor: 2.875
Publication type: Paper in international publication
Authors: Moreno-Palomares, J J, Esteban, Rafael, Buti, Maria, de Cuenca, Beatriz, Sanchez-Pobre, Pilar, Moreno, Diego, Fernandez-Bermejo, Miguel, Riveiro-Barciela, Mar, Tabernero, David, Calleja, Jose L et al.
DOI: 10.1007/s10620-017-4448-7

Blog

News

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Estudi sobre els patrons de consum habitual de l'alcohol en població jove

Des de Vall d'Hebron estem buscant 200 persones voluntàries sanes d'entre 18 i 30 anys per a participar en un estudi sobre els patrons de consum habitual de l'alcohol en població jove, en el marc del projecte StopALD.

Més informació